Article | June 12, 2023

FDA Releases Updated Draft Guidance On Decentralized Clinical Trials

Source: Harbor Clinical
GettyImages-1168902334 FDA

In May, the U.S. Food and Drug Administration released a revision to preliminary recommendations concerning the development and execution of decentralized clinical trials (DCTs). The draft document fulfills Section 3606(a) of the Food and Drug Omnibus Reform Act, requiring the FDA to issue guidance on DCTs by December 29, 2023.

As outlined by the revised draft guidance, regulators have defined DCTs as trials in which certain or all trial-related activities take place outside of conventional trial settings. Furthermore, the draft identifies scenarios that may gain advantages from a decentralized research approach and offers recommendations to sponsors to uphold patient safety and data security.

Take a closer look at draft guidance, notably the handling of remote trial visits, the use of digital health technologies, institutional review board oversight, and more.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Tech Leader? Subscribe today.

Subscribe to Clinical Tech Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Tech Leader